Equities

Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.86
  • Today's Change-0.437 / -10.17%
  • Shares traded1.30m
  • 1 Year change-78.05%
  • Beta1.3389
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

  • Revenue in USD (TTM)12.70m
  • Net income in USD-4.56m
  • Incorporated2006
  • Employees172.00
  • Location
    Sonoma Pharmaceuticals Inc5445 CONESTOGA COURT, SUITE 150BOULDER 80301United StatesUSA
  • Phone+1 (617) 243-0050
  • Fax+1 (707) 283-0551
  • Websitehttps://sonomapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunshine Biopharma Inc30.48m-3.68m3.36m44.00--0.1491--0.1103-194.01-194.011,017.8520.071.063.3310.19692,772.50-12.75-101.52-15.41-137.0430.4135.47-12.07-165.333.26--0.00--454.42--83.15--110.99--
Onconetix Inc1.46m-53.12m3.52m12.00------2.40-2.62-2.620.07231.270.03283.455.30121,979.20-119.09---215.11---57.21---3,629.24--0.091-11.870.2984-------176.78------
Shuttle Pharmaceuticals Holdings Inc0.00-7.20m3.70m8.00--0.5453-----10.29-10.290.003.040.00----0.00-123.53---147.27-------------4.320.5076-------112.71------
China Pharma Holdings Inc6.25m-4.40m3.88m231.00--0.5233--0.6205-0.6254-0.62540.63790.43170.4172.3423.5727,047.32-29.39-29.66-59.89-55.25-25.896.47-70.48-73.090.2449-21.220.277---13.48-10.6822.50---25.78--
Tian'an Pharmaceutical Co Ltd10.65m3.14m4.24m--0.02360.00511.160.39810.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Sonoma Pharmaceuticals Inc12.70m-4.56m4.41m172.00--0.8213--0.3473-10.07-10.0720.985.240.8592.914.4773,831.40-30.85-29.36-41.88-40.6538.1738.00-35.91-30.932.47--0.0394---4.05-7.666.13---29.84--
Stemtech Corp5.37m-5.11m4.44m45.00------0.8276-0.0518-0.05180.0529-0.03591.338.3942.31---126.26------77.87---95.16--0.065-2.59----7.94--36.45------
Silo Pharma Inc72.12k-3.45m4.57m3.00--0.637--63.42-1.16-1.180.02421.600.0079----24,040.00-37.69-24.90-43.50-26.3991.9082.79-4,777.02-2,757.85----0.00--0.00--7.07------
Processa Pharmaceuticals Inc0.00-10.22m4.62m13.00--0.6763-----5.36-5.360.002.100.00----0.00-115.58-84.35-133.48-90.03------------0.0016------59.45---34.05--
GT Biopharma Inc0.00-11.35m4.87m2.00--0.8845-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
CYANOTECH CORP23.82m-5.10m4.87m77.00--0.4563--0.2045-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
AgriFORCE Growing Systems Ltd57.60k-15.05m4.91m7.00--0.3873--85.17-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
Titan Pharmaceuticals Inc4.00k-5.46m5.17m4.00--1.30--1,293.64-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
Sonnet Biotherapeutics Holdings Inc55.89k-7.99m5.20m12.00--1.99--93.08-3.02-3.020.01440.50170.0071--0.08814,657.50-100.88---255.30-------14,287.67-----331.070.00---57.76--36.64------
Data as of Sep 19 2024. Currency figures normalised to Sonoma Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

2.11%Per cent of shares held by top holders
HolderShares% Held
Citadel Securities LLCas of 30 Jun 20249.76k0.95%
Geode Capital Management LLCas of 30 Jun 20244.33k0.42%
Jane Street Capital LLCas of 30 Jun 20242.27k0.22%
SSgA Funds Management, Inc.as of 30 Jun 20241.22k0.12%
HRT Financial LLCas of 30 Jun 20241.08k0.11%
XTX Markets LLCas of 30 Jun 2024992.000.10%
Two Sigma Securities LLCas of 30 Jun 2024766.000.08%
UBS Securities LLCas of 30 Jun 2024596.000.06%
Tower Research Capital LLCas of 30 Jun 2024413.000.04%
Qube Research & Technologies Ltd.as of 30 Jun 2024170.000.02%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.